MaaT Pharma Receives EMA Negative Trend Opinion on MaaT013 Conditional Marketing Authorization Application

A negative trend opinion from the CHMP on MaaT013 (Xervyteg®) signals the continued difficulty of advancing single-arm pivotal trial packages through Europe's Conditional Marketing Authorization pathway, a pressure point that regulatory affairs teams across the industry should read carefully. MaaT Pharma disclosed the outcome following its oral explanation before the EMA's Committee for Medicinal Products for Human Use, with a formal vote expected at the June CHMP meeting.

The company intends to request a re-examination of the application, a standard EMA procedure that triggers an independent scientific reassessment by a different reviewer panel. Under the EMA's procedural rules, the CHMP must complete re-examination within 60 calendar days of receiving the formal request. MaaT Pharma has characterized the CHMP's concerns as consistent with challenges typically encountered by first-in-class therapies supported by single-arm study designs rather than randomized controlled data.

MaaT013 is assessed under the CMA pathway, which is structured to permit earlier access to medicines addressing unmet medical needs while confirmatory post-approval data is generated. The ARES pivotal study underpins the dossier, supplemented by real-world evidence from an Early Access Program active across 13 countries, with more than 300 patients treated globally since 2019. That real-world dataset may carry additional weight during re-examination, though its sufficiency against CHMP evidentiary standards remains the central regulatory question.

On the operational side, MaaT Pharma has implemented cash management measures to extend financial visibility to November 2026, from a prior horizon of August 2026, specifically to cover the re-examination timeline and continued pipeline activity. For plant and supply chain leads supporting the Early Access Program, continuity of the manufacturing and distribution network through that window will be a near-term operational consideration.

The re-examination outcome will serve as a measurable indicator of how the EMA weighs real-world evidence and early-access data against the absence of a randomized comparator arm in novel therapeutic modality submissions under the CMA framework.

Source: MaaT Pharma via corporate press release, May 20, 2026.